Acute myeloid leukemia · 17 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
7+3d and GO Variant #01 | — | R 95 453 | 7d | — | — | 1 | R 95 453 PFS proxy | 1 |
DA 3+10, GO Variant #01 | — | R 54 619 | 10d | — | — | 1 | R 54 619 PFS proxy | 1 |
DAC Variant #01 | — | R 48 513 | 7d | — | 24.0 mo | 1 | R 48 513 PFS proxy | 1 |
FLAG-Ida Variant #01 | — | R 48 325 | 28d | — | ~5.4 mo | ~1 | ~R 48 325 PFS proxy · indirect | 3 |
7+3i and Sorafenib Variant #01 | — | R 26 353 | 7d | — | — | ~1 | ~R 26 353 indirect | — |
ADE (high-dose Ara-C) Variant #01 | — | R 25 902 | 6d | — | — | 1 | R 25 902 PFS proxy | 1 |
AIE Variant #01 | — | R 20 821 | 7d | — | — | ~1 | ~R 20 821 indirect | — |
ICL Variant #01 Partial | — | R 20 091 | 7d | — | — | 1 | R 20 091 PFS proxy | 1 |
7+3i Variant #01 | — | R 18 145 | 7d | — | 12.9 mo | 1 | R 18 145 PFS proxy | 2 |
7+3m Variant #01 | — | R 13 839 | 7d | — | ~6.7 mo | ~1 | ~R 13 839 PFS proxy · indirect | 1 |
ADE (standard-dose Ara-C) Variant #07 | — | R 13 353 | 10d | — | — | 1 | R 13 353 PFS proxy | 1 |
7+3d and Glasdegib Variant #01 Partial | — | R 12 452 | 28d | — | — | ~1 | ~R 12 452 indirect | — |
DA 3+10 Variant #01 | — | R 11 640 | 10d | — | — | 1 | R 11 640 PFS proxy | 2 |
CIA Variant #01 Partial | — | R 9 614 | 5d | — | — | ~6 | ~R 57 686 indirect | — |
MEC Variant #01 | — | R 9 564 | 28d | — | 10.0 mo | 1 | R 9 564 PFS proxy | 1 |
7+3d Variant #01 | — | R 6 538 | — | — | 15.1 mo | 2 | R 13 076 PFS proxy | 11 |
HAA Variant #01 Partial | — | R 624 | 7d | — | — | ~1 | ~R 624 indirect | — |
17 of 17 regimens shown